3,292 Astrazeneca Plc $AZN Shares Sold by Quadrant Capital Group LLC

Quadrant Capital Group LLC decreased its position in Astrazeneca Plc (NYSE:AZN) by 6.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 47,242 shares of the company’s stock after selling 3,292 shares during the quarter. Quadrant Capital Group LLC’s holdings in Astrazeneca were worth $7,361,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Mascoma Wealth Management LLC bought a new stake in Astrazeneca in the first quarter worth about $26,000. Roxbury Financial LLC bought a new position in shares of Astrazeneca during the 2nd quarter valued at about $29,000. Resources Management Corp CT ADV bought a new position in shares of Astrazeneca during the 1st quarter valued at about $35,000. Allied Private Wealth LLC bought a new position in shares of Astrazeneca during the 2nd quarter valued at about $35,000. Finally, GK Wealth Management LLC acquired a new position in shares of Astrazeneca in the 3rd quarter worth approximately $31,000. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Stock Performance

Shares of NYSE AZN opened at $168.97 on Wednesday. The stock’s fifty day simple moving average is $162.41 and its 200 day simple moving average is $175.46. The stock has a market capitalization of $262.05 billion, a price-to-earnings ratio of 16.89, a PEG ratio of 1.38 and a beta of 0.27. The company has a quick ratio of 0.67, a current ratio of 0.89 and a debt-to-equity ratio of 0.47. Astrazeneca Plc has a 52-week low of $153.41 and a 52-week high of $212.71.

Astrazeneca (NYSE:AZN) last announced its earnings results on Monday, July 27th. The company reported $2.63 EPS for the quarter, beating the consensus estimate of $2.50 by $0.13. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%. The business had revenue of $15.38 billion during the quarter, compared to the consensus estimate of $15.44 billion. During the same period in the prior year, the business posted $2.17 earnings per share. Astrazeneca’s revenue was up 6.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Astrazeneca Plc will post 9.38 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on AZN. The Goldman Sachs Group reiterated a “buy” rating on shares of Astrazeneca in a report on Wednesday, July 1st. Royal Bank Of Canada started coverage on shares of Astrazeneca in a research note on Tuesday, September 8th. They set an “outperform” rating for the company. Deutsche Bank Aktiengesellschaft upgraded shares of Astrazeneca from a “sell” rating to a “hold” rating in a report on Tuesday, September 15th. Wall Street Zen cut shares of Astrazeneca from a “buy” rating to a “hold” rating in a report on Sunday, October 11th. Finally, CICC Research initiated coverage on shares of Astrazeneca in a research report on Sunday, August 23rd. They issued an “outperform” rating and a $198.00 price target on the stock. Fifteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $206.67.

Astrazeneca Profile

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.

AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.